COVID-19 and emerging viral infections: The case for interferon lambda

Authors list

Ludmila Prokunina-Olsson Noémie Alphonse Ruth E Dickenson Joan E Durbin Jeffrey S Glenn Rune Hartmann Sergei V Kotenko Helen M Lazear Thomas R O’Brien Charlotte Odendall Olusegun O Onabajo Helen Piontkivska Deanna M Santer Nancy C Reich Andreas Wack Ivan Zanoni
Scroll for detail on labs, facilities & authors

Abstract

With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.

Journal details

Journal Journal of Experimental Medicine
Volume 217
Issue number 5
Pages e20200653
Available online
Publication date

Full text links

Publisher website (DOI) 10.1084/jem.20200653
Europe PubMed Central 32289152
Pubmed 32289152

Keywords

Related topics
Type of publication

Crick labs/facilities

Crick authors

Crick First author
Crick Corresponding author

Related content